Search references for OLESOXIME. Phrases containing OLESOXIME
See searches and references containing OLESOXIME!OLESOXIME
Chemical compound
Olesoxime (TRO19622) is an experimental drug formerly under development by the now-defunct French company Trophos as a treatment for a range of neuromuscular
Olesoxime
entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622), a mitochondrial targeted compound developed to treat neurodegenerative
Trophos
Benzodiazepine sedative
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
Diazepam
Swiss multinational healthcare company
deal will centre on the Phase II and III spinal muscular atrophy drug olesoxime (TRO19622). In April 2015, Roche acquired CAPP Medical, and its chief
Roche
Protein-coding gene in the species Homo sapiens
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
Diazepam_binding_inhibitor
Rare congenital neuromuscular disorder
enabling the survival of motor neurons even with low levels of SMN protein. Olesoxime was a proprietary neuroprotective compound developed by the French company
Spinal_muscular_atrophy
Human protein
DPA-713 DPA-714 Emapunil Etifoxine Gidazepam FGIN-127 FGIN-143 GML-1 Olesoxime (TRO19622) SSR-180,575 PK-11195 - potent and selective antagonist for
Translocator_protein
Anxiolytic medication
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
Etifoxine
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
Emapunil
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
Dithranol
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
DPA-713
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
DPA-714
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
Deuterated_etifoxine
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
GML-1
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
Ro5-4864
Protein-coding gene in the species Homo sapiens
models of Huntington's disease, treatment with the VDAC-targeting compound olesoxime improved disease-associated phenotypes, possibly by modulating calcium
VDAC1
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
PK_11195
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
DAA-1097
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
DAA-1106
Medical research on ALS
mitochondria function (creatine, acetyl-L-carnitine, dexpramipexole, and olesoxime). Other drugs with a variety of mechanisms were tested in clinical trials
Amyotrophic lateral sclerosis research
Amyotrophic_lateral_sclerosis_research
Anxiolytic medication
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
Alpidem
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
W-18_(drug)
Chemical compound
binding inhibitor (DBI) DPA-713 DPA-714 Emapunil Etifoxine FGIN-1-27 FGIN-1-43 GML-1 Olesoxime Ro5-4864 SSR-180,575 W-18 YL-IPA08 Antagonists PK-11195
SSR-180,575
travel, tourism, insurance
OLESOXIME
OLESOXIME
OLESOXIME
OLESOXIME
OLESOXIME
OLESOXIME
OLESOXIME
OLESOXIME
OLESOXIME
travel, tourism, insurance